Musi wa9 Kukadzi 2026, webhusaiti yepamutemo yeCenter for Drug Evaluation (CDE) yeNational Medical Products Administration (NMPA) yakazivisa kuti ZL-1310 yekubaiwa jekiseni, mushonga mutsva weDLL3-targeting antibody-drug conjugate (ADC), wakarongwa kupihwa Breakthrough Therapy Designation.
Senhengo yePeking University Cancer Hospital Medical Consortium uye chipatara cheBeijing secondary modern oncology specialized, Beijing South Region Oncology Hospital International Department inoshandisa nzira yakasimba yekuongorora nekurapa kurapa dzinosanganisira nzira dzekurapa dzinotungamira pasi rose nekukurumidza muzvirongwa zvekurapa varwere vekunze kwenyika. Kana iwe kana mudiwa wako ari kutarisana nematambudziko ekurapwa kwekenza yemapapu yemasero madiki kana kuti gare gare, ndapota verenga data riri pazasi uye taura nesu nekukasika.
Bata Dhipatimendi reBeijing South Region Oncology Hospital International izvozvi:
- Nhare: 400-880-3716
- WeChat ID: 17801183037
- Email ①: 100085_010@163.com
- Email ②: myimmnet@163.com
**Data Rakaoma: Kusvika 86% Kushanda Kwevarwere Vane Brain Metastases**
PaMusangano weGore negore weAmerican Society of Clinical Oncology (ASCO) wa2025, data repasi rose rekudzidza kwekiriniki reZL-1310 rakaburitswa.
Kune varwere vakamborapwa (kurapwa kwechipiri):
- Chiyero chekupindura chakasimbiswa (uORR) chakasvika 67%, nechiyero chekudzora chirwere (DCR) che97%.
- Muboka remhando yepamusoro yedosi (1.6 mg/kg): Mwero wemhinduro yechinangwa (ORR) wakakwira kusvika pa79%, nemwero wekutonga chirwere (DCR) we100%.
- Izvi zvinoreva kuti: Varwere vanenge gumi vese vakapihwa mushonga uyu vakakwanisa kudzora bundu, uye varwere vanosvika vasere vakatambura nekuderera kukuru kwebundu.
Kune varwere vanonyanya kunetseka vane uropi hwakanyanya kupararira:
- Varwere vane chirwere chepfungwa chepakutanga: Chiyero chekupindura kwechinangwa (ORR) chaive 68%.
- Varwere vasina kumbobvira vawana kurapwa nemwaranzi yemusoro: Chiyero chekupindura chakanangana (ORR) chakakwira kusvika 86%!
Ruzivo urwu rwunoshamisa. Mishonga yechinyakare yechemotherapy inonetseka kupinda muropa-uropi, asi ZL-1310 inoratidza kushanda kwakasimba kwekudzivirira bundu mukati memusoro. Kune varwere vekune dzimwe nyika vane hanya nemhedzisiro yekurapa neradiotherapy yeuropi hwese, izvi zvinomirira tariro huru "yekudzivirira mwaranzi yeuropi."
**Profile yeKuchengetedzeka:** Muboka re<2.0 mg/kg yedosi, kuwanda kwezviitiko zvakashata zvine chekuita nekurapwa (TRAEs) zvegiredhi rechitatu kana kupfuura kwaive 6% chete, pasina zviitiko zvine chekuita nekurapwa zvine chekuita nekurapwa (ILD) kana zviitiko zvekumira kurapwa zvakataurwa.
—
**III. Sei Uchifanira Kusarudza Dhipatimendi Repasirose reBeijing South Region Oncology Hospital?**
Kune varwere vekune dzimwe nyika, kuwana mishonga mitsva hakusi kungotaura nezvekuti "mushonga wacho unowanikwa here," asiwo maitiro akarongeka anosanganisira "kuti ndiani anogona kuushandisa, mashandisirwo awo, uye kuti ndiani anotarisira migumisiro yacho."
Dhipatimendi reBeijing South Region Oncology Hospital International rinopa ongororo dzinotarisirwa uye manejimendi yakazara yekurapa kwemhando yepamusoro senge ZL-1310 kune varwere vanokodzera. Kunyangwe uri wekuSoutheast Asia, Middle East, Europe, kana America, tine nzira yekurapa yepasi rose yakasimbiswa.
Tinopa mabasa akazara kubva pakubvunzana usati waenda kuchipatara, kushandura mitauro yakawanda, tsamba dzevhiza yekurapa, kusvika pakuteverwa kwekugadziriswa kwemuviri. Kunyatsotevedzera mutemo wekuti "chiremba mumwe, murwere mumwe, kamuri rimwe" kunoita kuti kuvanzika kwako nerukudzo zviremekedzwe zvizere, kunyangwe munyika yekune imwe nyika.
Parizvino, ZL-1310 yakapihwa basa rekuti Orphan Drug uye Fast Track Designation neUS FDA. Kuiswa kwayo muBreakthrough Therapy Designation yeChina kuchakurumidzisa kuwanikwa kwayo muChina.
Usarega zvipingamupinyi zvemutauro, kusawana ruzivo rwakakwana, kana nzira dzakaoma dzichikutadzisa kuwana mishonga yepamusoro. Dhipatimendi reBeijing South Region Oncology Hospital International rakagadzira nzira yekubatsira varwere vekune dzimwe nyika.
Tora runhare kana kutibata nesu kuburikidza neWeChat kana email kuti ugovane mamiriro ako ezvinhu. Vanachipangamazano vedu vezvehutano vachakupa ongororo yekutanga mukati memaawa makumi maviri nemana.
- Nhare (kubvunzana kwemaawa makumi maviri nemana): 400-880-3716
- WeChat (kutaurirana ipapo ipapo): 17801183037 (inotsigira Chirungu nechiChinese)
- Email (yezvinyorwa zvekurapa):
- 100085_010@163.com
- myimmnet@163.com
Nguva yekutumira: Kukadzi-12-2026